Sophie Laberge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophie Laberge has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth Tournier-Lasserve
Department of Neurovascular Molecular Genetics AP-HP, Saint-Louis Hospital, 75010 Paris, France
6 shared publications Pierre Labauge
6 shared publications- Florian Clatot
Centre Henri Becquerel, Rouen, France
5 shared publications Marie Cornic
Department of Pathology
5 shared publicationsJean-Michel Picquenot
INSERM U918, Department of Pathology
4 shared publicationsAnne Vincent-Salomon
Groupe d'étude des facteurs pronostiques immunohistochimiques dans le cancer du sein, Unicancer, 101, rue de Tolbiac, 75654 Paris cedex 13, France
3 shared publications
Latest Publications
- 1 January 2016
- Vol. 36 (1) , 435-437
Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry for Breast Cancer
Background: SP1 Rabbit monoclonal antibody to estrogen receptor (ER) has long been the standard for determination of ER status in breast cancer but has been replaced by the rabbit EP1 clone. Aim: To validate the EP1 antibody clone for use in determination of breast cancer ER status in a large clinical population against the previous standard SP1. Materials and Methods: ER immunohistochemistry was assessed in 523 consecutive cases from a clinical setting using tissue microarrays. Results: The kappa statistic showed that the agreement of ER status between SP1 and EP1 was considered to be almost perfect (kappa=0.97, 95% confidence interval=0.94-1.00). Sensitivity was 99.3%, specificity was 98.6% and overall agreement was 99.2%. Conclusion: The EP1 antibody was herein validated regarding its use in breast cancer with almost perfect agreement with the previously used standard SP1 antibody.
- 1 January 2016
- Vol. 36 (1) , 435-437
Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry for Breast Cancer
Background: SP1 Rabbit monoclonal antibody to estrogen receptor (ER) has long been the standard for determination of ER status in breast cancer but has been replaced by the rabbit EP1 clone. Aim: To validate the EP1 antibody clone for use in determination of breast cancer ER status in a large clinical population against the previous standard SP1. Materials and Methods: ER immunohistochemistry was assessed in 523 consecutive cases from a clinical setting using tissue microarrays. Results: The kappa statistic showed that the agreement of ER status between SP1 and EP1 was considered to be almost perfect (kappa=0.97, 95% confidence interval=0.94-1.00). Sensitivity was 99.3%, specificity was 98.6% and overall agreement was 99.2%. Conclusion: The EP1 antibody was herein validated regarding its use in breast cancer with almost perfect agreement with the previously used standard SP1 antibody.
- Open Access
- 1 October 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (4) , 555-562
Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors
Objectives:. Preoperative biopsy of breast cancer allows for prognostic/predictive marker assessment. However, large tumors, which are the main candida
- 1 October 2015
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 144 (4) , 555-562
Open AccessReliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors
Objectives:. Preoperative biopsy of breast cancer allows for prognostic/predictive marker assessment. However, large tumors, which are the main candida
- 1 October 2014
- Published by Elsevier in Annales de Pathologie
- Vol. 34 (5) , 352-365
Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
- 1 October 2014
- Published by Elsevier in Annales de Pathologie
- Vol. 34 (5) , 352-365
Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
- 1 October 2014
- Published by Elsevier in Annales de Pathologie
- Vol. 34 (5) , 366-372
Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014
- 1 October 2014
- Published by Elsevier in Annales de Pathologie
- Vol. 34 (5) , 366-372
Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014
- 1 September 2014
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 22 (8) , 613-618
Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer
Estrogen receptor (ER) tumor's status is critical for breast cancer management. A new rabbit antibody clone, EP1, is now available for ER status determination. The objective was to validate the EP1 antibody clone for its use in breast cancer ER status determination in a clinical setting against the previous standard, SP1. EP1 clone was assessed in 130 consecutive cases, including 50 ER-negative (<1% ER expression), 13 ER-low-positive (1% to 9% ER expression), and 67 ER-positive (≥10% ER expression). Using EP1 versus SP1, positive agreement (sensibility) was 92.5% and negative agreement (specificity) was 100%, leading to an overall agreement of 95.4%. All discordant cases (n=6) were ER-low-positive. SP1 was remeasured in 13 ER-low-positive and in 11 ER-negative cases. Overall agreement between SP1 initial tumor status and reassessment was 70.8% in those negative and low-positive cases. In conclusion, EP1 antibody has been validated for use in breast cancer with a positive agreement ≥90% and a negative agreement ≥95%, as recommended. Also, overall agreement between EP1 and SP1 was as good as between the SP1 initial status and SP1 reassessment.
- 1 September 2014
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 22 (8) , 613-618
Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer
Estrogen receptor (ER) tumor's status is critical for breast cancer management. A new rabbit antibody clone, EP1, is now available for ER status determination. The objective was to validate the EP1 antibody clone for its use in breast cancer ER status determination in a clinical setting against the previous standard, SP1. EP1 clone was assessed in 130 consecutive cases, including 50 ER-negative (<1% ER expression), 13 ER-low-positive (1% to 9% ER expression), and 67 ER-positive (≥10% ER expression). Using EP1 versus SP1, positive agreement (sensibility) was 92.5% and negative agreement (specificity) was 100%, leading to an overall agreement of 95.4%. All discordant cases (n=6) were ER-low-positive. SP1 was remeasured in 13 ER-low-positive and in 11 ER-negative cases. Overall agreement between SP1 initial tumor status and reassessment was 70.8% in those negative and low-positive cases. In conclusion, EP1 antibody has been validated for use in breast cancer with a positive agreement ≥90% and a negative agreement ≥95%, as recommended. Also, overall agreement between EP1 and SP1 was as good as between the SP1 initial status and SP1 reassessment.
- 1 April 2013
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 34 (4) , 340-346
Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma
In patients thyroidectomized for well-differentiated thyroid carcinoma, the correlation between thyroglobulin (Tg) plasma level and F-fluoro-2-deoxy-D-glucose (F-FDG)-PET results is still a matter of debate. We evaluated whether the immunochemical profile of the primary tumour could be used as a predictor of positivity on F-FDG-PET/computed tomography (CT) when recurrence is confirmed. A total of 26 patients (eight men, 18 women; 51±16 years old) were included. All of the patients had a histologically proven recurrence or a high level of Tg during follow-up and underwent a F-FDG-PET/CT following two intramuscular injections of rhTSH. The F-FDG-PET/CT scans were blindly analysed by three nuclear physicians. The results of the PET scans were classified as true positive, false positive or false negative. Nine antibodies were used for the immunochemical analysis (tissue microarray: hexokinase I, II and III; Tg; vascular endothelial growth factor; and glucose transporter type 1, CD31, CD68 and sodium iodide symporter). The PET scans were positive for 15 patients and negative for 11 patients. Hexokinase I was expressed in nine of the 26 primary tumours (7/26 for the isoforms). No single molecule expressed in the primary tumours was correlated with the F-FDG-PET/CT results. There was no association of antibody overexpression (clustering) in the primary tumours with the F-FDG-PET/CT results of the recurrences. In a larger series, we failed to confirm the preliminary results of Hooft and colleagues. This study did not allow for the determination of a single marker expressed in the primary tumours that would be predictive of F-FDG-PET/CT positivity when recurrence is suspected. Therefore, at present, immunochemistry does not appear to be a definitive tool for predicting the results of F-FDG-PET/CT in cases of recurrence.
- 1 April 2013
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 34 (4) , 340-346
Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma
In patients thyroidectomized for well-differentiated thyroid carcinoma, the correlation between thyroglobulin (Tg) plasma level and F-fluoro-2-deoxy-D-glucose (F-FDG)-PET results is still a matter of debate. We evaluated whether the immunochemical profile of the primary tumour could be used as a predictor of positivity on F-FDG-PET/computed tomography (CT) when recurrence is confirmed. A total of 26 patients (eight men, 18 women; 51±16 years old) were included. All of the patients had a histologically proven recurrence or a high level of Tg during follow-up and underwent a F-FDG-PET/CT following two intramuscular injections of rhTSH. The F-FDG-PET/CT scans were blindly analysed by three nuclear physicians. The results of the PET scans were classified as true positive, false positive or false negative. Nine antibodies were used for the immunochemical analysis (tissue microarray: hexokinase I, II and III; Tg; vascular endothelial growth factor; and glucose transporter type 1, CD31, CD68 and sodium iodide symporter). The PET scans were positive for 15 patients and negative for 11 patients. Hexokinase I was expressed in nine of the 26 primary tumours (7/26 for the isoforms). No single molecule expressed in the primary tumours was correlated with the F-FDG-PET/CT results. There was no association of antibody overexpression (clustering) in the primary tumours with the F-FDG-PET/CT results of the recurrences. In a larger series, we failed to confirm the preliminary results of Hooft and colleagues. This study did not allow for the determination of a single marker expressed in the primary tumours that would be predictive of F-FDG-PET/CT positivity when recurrence is suspected. Therefore, at present, immunochemistry does not appear to be a definitive tool for predicting the results of F-FDG-PET/CT in cases of recurrence.
- 1 July 2012
- Published by Elsevier in Bulletin du Cancer
- Vol. 99 (7-8) , 771-778
Carcinomes épidermoïdes primitifs du sein : étude clinique et revue de la littérature
From the analysis of our series and a review of the literature, we have done a summary of the clinicopathologic patterns and treatment of squamous cell carcinoma of the breast. It usually presents as a large palpable mass in a woman over 50 years old. There are no specific iconographic features, but a relative frequency of presentation as abscess or cyst. The overall and disease-free survivals are worse than other histological types of breast cancer. These neoplasms have a basal-like and triple negative profile and they respond poorly to standard treatment of breast carcinomas. They are usually treated by radical surgery. Optimal chemotherapy regimens is not yet determined and platin based chemotherapy could offer an effective alternative as the developpement of specific targeted therapies (anti Her1) could do.
- 1 July 2012
- Published by Elsevier in Bulletin du Cancer
- Vol. 99 (7-8) , 771-778
Carcinomes épidermoïdes primitifs du sein : étude clinique et revue de la littérature
From the analysis of our series and a review of the literature, we have done a summary of the clinicopathologic patterns and treatment of squamous cell carcinoma of the breast. It usually presents as a large palpable mass in a woman over 50 years old. There are no specific iconographic features, but a relative frequency of presentation as abscess or cyst. The overall and disease-free survivals are worse than other histological types of breast cancer. These neoplasms have a basal-like and triple negative profile and they respond poorly to standard treatment of breast carcinomas. They are usually treated by radical surgery. Optimal chemotherapy regimens is not yet determined and platin based chemotherapy could offer an effective alternative as the developpement of specific targeted therapies (anti Her1) could do.
- 1 November 2011
- Published by Elsevier in Oral Oncology
- Vol. 47 (11) , 1062-1068
Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma
- 1 November 2011
- Published by Elsevier in Oral Oncology
- Vol. 47 (11) , 1062-1068
Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma
- 7 December 2010
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 38 (12) , 767-769
Un ganglion pelvien « bleu ». Quel est votre diagnostic ?
- 7 December 2010
- Published by Elsevier in Gynécologie Obstétrique & Fertilité
- Vol. 38 (12) , 767-769
Un ganglion pelvien « bleu ». Quel est votre diagnostic ?